Amylyx Pharmaceuticals (NASDAQ:AMLX) Posts Earnings Results, Misses Estimates By $0.03 EPS
by Doug Wharley · The Cerbat GemAmylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03), FiscalAI reports.
Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:
- Avexitide LUCIDITY randomized and dosed its last participant in late March and remains on track to complete the 16-week trial with a top-line readout expected in Q3 2026, while NDA sections are already being drafted to support a potential 2027 approval and launch if results are positive.
- The company launched a U.S. expanded access program for up to 250 adults, is initiating a disease‑state education campaign this summer, and cites an independent claims-based market estimate of ~160,000 people in the U.S. with PBH, with endocrinologists showing high intent to treat if an approved therapy becomes available.
- Amylyx reported $279.8 million in cash and marketable securities and says this capital funds an anticipated cash runway into 2028, covering key milestones including the LUCIDITY readout and potential commercialization activities.
- Broader pipeline progress includes IND‑enabling work for the long‑acting GLP‑1 antagonist AMX0318 (targeting a 2027 IND), forthcoming week‑96 data for AMX0035 in Wolfram syndrome, and biomarker data from cohort 1 of the AMX0114 ALS trial expected at an upcoming scientific meeting.
- Q1 operating expenses rose to $43.8 million (up 16% year‑over‑year) driven by higher R&D spend on avexitide and a $4.0 million milestone payment to Gubra, and the company reported slightly higher cash usage this quarter due to that payment and annual bonuses.
Amylyx Pharmaceuticals Trading Down 5.4%
Shares of NASDAQ:AMLX traded down $0.86 during trading on Thursday, hitting $15.20. 1,451,469 shares of the stock were exchanged, compared to its average volume of 1,021,572. The company has a fifty day moving average price of $15.36 and a two-hundred day moving average price of $14.26. The company has a market cap of $1.69 billion, a PE ratio of -9.81 and a beta of -0.11. Amylyx Pharmaceuticals has a 12-month low of $4.20 and a 12-month high of $18.60.
Institutional Investors Weigh In On Amylyx Pharmaceuticals
Several institutional investors have recently modified their holdings of the company. Landscape Capital Management L.L.C. boosted its stake in shares of Amylyx Pharmaceuticals by 17.5% during the 4th quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock worth $148,000 after acquiring an additional 1,825 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $25,000. The Manufacturers Life Insurance Company boosted its stake in shares of Amylyx Pharmaceuticals by 13.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company’s stock worth $326,000 after acquiring an additional 3,198 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Amylyx Pharmaceuticals by 1,116.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock worth $54,000 after acquiring an additional 4,088 shares in the last quarter. Finally, California State Teachers Retirement System purchased a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $28,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.
Analysts Set New Price Targets
AMLX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 25th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a report on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 price objective on the stock. Guggenheim lifted their price objective on Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Mizuho lifted their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Finally, Bank of America lifted their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.00.
View Our Latest Stock Report on AMLX
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.